Survodutide
Stories
-
Survodutide shows no increased cardiovascular risk in obesity trial
The authors reported that in the SYNCHRONIZE-CVOT phase 3 trial, 136 of 3671 participants receiving survodutide experienced the primary composite endpoint versus 76 of 1836 receiving placebo (HR 0·89 [95% CI 0·67-1·18]). Gastrointestinal adverse events were more frequent with survodutide, with nausea in 48·0%-49·0% and vomiting in 31·7%-34·0% of participants.
-
Boehringer Ingelheim registers Phase 3b trial of Survodutide in MASLD
This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 600 participants and planned start date is October 23, 2026.
-
Boehringer Ingelheim registers study of survodutide in overweight or obesity without diabetes
This study was first posted on ClinicalTrials.gov on October 2, 2026. The Phase IIIb, open-label study plans to enroll 350 participants, with a planned start date of November 7, 2026 and a primary completion date of June 25, 2028.